Related Experiment Video
Updated: Jan 10, 2026
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
8.8K
Precision therapeutics for Alzheimer's disease.
S Priyanka1, T Manjari1, S Hemalatha1
1PG & Research Department of Chemistry, Bishop Heber College, Trichy, India.
Progress in Brain Research
|November 28, 2025
Summary
Precision medicine offers tailored Alzheimer's disease (AD) treatments by considering individual profiles. This approach explores advanced therapies like gene editing and monoclonal antibodies for better outcomes.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with significant cognitive decline.
- Current treatments for AD are limited, highlighting the need for novel therapeutic strategies.
- The accumulation of amyloid-beta plaques and tau tangles are hallmarks of AD pathology.
Purpose of the Study:
- To explore advancements in precision therapeutics for Alzheimer's disease.
- To discuss the potential of individualized treatment strategies in managing AD.
- To review emerging and innovative therapeutic approaches for AD.
Main Methods:
- Review of current literature on precision medicine in AD.
- Analysis of biomarker-driven therapies and pharmacogenomics.
- Exploration of novel therapeutic agents including monoclonal antibodies, RNA-based therapeutics, stem cells, and gene editing.
Main Results:
- Precision medicine enables customized interventions based on genetic, molecular, and lifestyle factors.
- Biomarker-driven therapies, pharmacogenomics, and targeted agents show promise for AD treatment.
- Emerging innovations like RNA therapeutics, stem cells, and CRISPR offer new avenues for AD management.
Conclusions:
- Precision medicine holds significant promise for developing effective, individualized Alzheimer's disease treatments.
- Addressing challenges in clinical translation, patient stratification, and regulation is crucial for successful implementation.
- Integrating cutting-edge research with clinical practice is key to advancing personalized AD care.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
517
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
517
01:30Dementia
487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
487
01:24Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
02:30siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K